Citations

Clear

2303 citation(s) found for "Yu, Edward".

Early Versus Late Computed Tomography and Nasal Endoscopy in the Diagnosis of Nasopharyngeal and Paranasal Sinus Malignancy
Marino, Michael J. , Hsieh, Mei‐Chin , Wu, Eric , Riley, Charles A. , Wu, Xiao‐Cheng , McCoul, Edward D.

Mayo Clinic

American Journal of Rhinology & Allergy | March 22, 2019 | Volume: 33 | Issue: 4 | Pages: 388-394

10.1177/1945892419838106 | PMID 30900468 Get It

Background Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) may be associated with an increased risk of subsequent diagnosis of nasopharyngeal carcinoma (NPC) or paranasal sinus cancer (PSC) in elderly Americans. The clinical utility of this association remains uncertain. Objective To compare early computed tomography (CT) or nasal endoscopy (NE) with late diagnostic studies for the diagnosis of NPC or PSC in elderly Americans with CRS or AR. Methods The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was queried from 2003 to 2011 and included 150 088 Medicare beneficiaries. Patients with a diagnosis of CRS or AR were examined for either NE or CT performed within 6 months of the exposure diagnosis. The risk of a cancer diagnosis was determined between the early and the late diagnostic groups. Results The relative risk of early cancer diagnosis with NE was 1.98 (95% confidence interval [CI], 1.60–2.43). The number needed to detect (NND) a case of cancer with NE was 503 (95% CI, 387–718). The relative risk of an early cancer diagnosis using CT was 3.40 (95% CI, 2.85–4.06) and NND was 221 (95% CI, 194–255). The stage of NPC or PSC for the late diagnostic group was not different from those with early NE ( P = .458) or CT ( P = .497). Overall survival was not different between diagnostic groups for NE ( P = .789) or CT ( P = .425). Conclusions Early NE or CT is associated with a higher likelihood of cancer diagnosis in elderly individuals with a diagnosis of CRS or AR. The clinical utility of this association is limited due to the low prevalence of these malignancies and lack of difference in disease stage and overall survival between diagnostic groups.
Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.
Naughton, Michelle J. , Earle, Craig C. , Höchster, Howard S. , Blanke, Charles D. , Schrag, Deborah , Dueck, Amylou C. , Niedzwiecki, Donna , Shaw, James Edward , Grothey, Axel , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6504-6504

10.1200/jco.2015.33.15_suppl.6504 Get It

Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. , Fruth, Briant, Kunz, Pamela L. , Kennecke, Hagen F. , Wolin, Edward M. , Niedzwiecki, Donna , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4005-4005

10.1200/jco.2015.33.15_suppl.4005 Get It

Sporadic angiomyolipomas (AMLs) growth kinetics while on everolimus (SAGE).
Kadow, Brian T. , Shuch, Brian , Boorjian, Stephen A. , Rampersaud, Edward N. , McClean, Daniel, Milestone, Barton N., Zibelman, Matthew R. , Smaldone, Marc C., Viterbo, Rosalia, Joshi, Shreyas , Greenberg, Richard E. , Malizzia, Lois, McGowan, Thomas, Geynisman, Daniel M. , Matin, Surena F. , Plimack, Elizabeth R. , Kutikov, Alexander , Chen, David , McGowan, Thomas, Ross, Eric A. , Uzzo, Robert G.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 560-560

10.1200/jco.2019.37.7_suppl.560 Get It

560 Background: Level I evidence exists demonstrating the efficacy of the mTOR inhibitor everolimus (EVE) in decreasing tumor volume of syndromic angiomyolipomas (AMLs) among patients with Tuberous Sclerosis. No prospective data are available regarding the effect of mTOR inhibition on growth kinetics in patients with sporadic AMLs. Methods: We conducted a multi-institutional, prospective, phase 2 trial with an optimal two-stage Simon design in patients presenting with > 3cm sporadic AMLs who were candidates for surgical or percutaneous intervention. Response was defined as ≥25% volumetric reduction of the AML. Planned enrollment was 43 patients to test the null hypothesis at a 5% level of significance with 80% power. Baseline, 4- and 6-month volumetric analysis was performed by dynamic contrast-enhanced MRI (DCE-MRI). Patients received EVE 10mg for four 28-day cycles, at which point EVE was discontinued in those with < 25% volumetric reduction. Those with ≥ 25% volumetric reduction received two additional cycles of EVE. Dose reductions and interruptions were allowed to 5 mg QOD. Conservative stopping rules were established for toxicity, given the benign nature of AMLs. Results: The early stopping rules for both efficacy and toxicity were invoked. We enrolled 20 patients (median age = 68) from 5 centers with 21 sporadic AMLs. 11/20 (55%) patients completed 4 cycles of EVE, while 7/20 (35%) completed 6 cycles. Median days on treatment was 88 (2 cycles). 4/20 (20%) patients were withdrawn due to toxicity, while 8/20 (40%) withdrew due to personal preference. Dose reductions were required in 6/20 (30%) patients, and 5/20 (25%) patients had grade 3 toxicities which resolved upon discontinuation or dose reduction of EVE. At 4-month MRI, 10/16 (62.5%) patients had a ≥25% reduction in volume (mean = 54.1% decrease). At 6-month MRI, 8/12 (66.6%) patients had a ≥25% reduction in volume (mean = 51.5% decrease). Conclusions: EVE was effective in reducing tumor volume in patients with sporadic AMLs but was associated with a high rate of treatment termination due to patient preference or prespecified AEs. Neoadjuvant EVE may be useful in potentiating surgical resection of large or anatomically complex AMLs. Clinical trial information: NCT02539459.
Recalibration of genomic risk prediction models in prostate cancer to improve individual-level predictions.
Choeurng, Voleak, Luo, Bin , Yousefi, Kasra, Shin, Heesun , Haddad, Zaid , Ross, Ashley E. , Dicker, Adam P. , Karnes, R. Jeffrey , Thompson, Darby J. S., Dicker, Adam P , Davicioni, Elai , Schaeffer, Edward M. , Den, Robert B.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e16122-e16122

10.1200/jco.2015.33.15_suppl.e16122 Get It

SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127).
Guthrie, Katherine A. , Moran, César A. , Kulke, Matthew H. , Chan, Jennifer A. , LoConte, Noelle K. , Wolin, Edward M. , Mattar, Bassam, McDonough, Shannon, Chen, Helen X., Blanke, Charles D. , Höchster, Howard S. , LoConte, Noelle , Yao, James C. , Strosberg, Jonathan , McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4004-4004

10.1200/jco.2015.33.15_suppl.4004 Get It

M itochondrial c erebellar a taxia, r enal failure, n europathy, and e ncephalopat
Ng, Peng Soon, Pinto, Marcus Vinícius , Neff, Jadee , Hasadsri, Linda , Highsmith, Edward W., Fidler, Mary E., Gavrilova, Ralitza H. , Pinto, Marcus V , Klein, Christopher J.

Mayo Clinic

Neurology Genetics | March 7, 2019 | Volume: 5 | Issue: 2 | Pages: No page available

10.1212/nxg.0000000000000314 | PMID 31041396 Get It

Effect of Trinucleotide Repeat Expansion on the Expression ofTCF4mRNA in Fuchs' Endothelial Corneal Dystrophy
Okumura, Naoki , Hayashi, Ryosuke , Nakano, Masakazu , Yoshii, Kengo, Tashiro, Kei, Blake, Derek J. , Aleff, Ross A., Butz, Malinda L., Highsmith, Edward W., Wieben, Eric D. , Fautsch, Michael P. , Baratz, Keith H. , Komori, Yuya, Nakahara, Makiko , Tourtas, Theofilos , Schlötzer‐Schrehardt, Ursula , Kruse, Friedrich E., Koizumi, Noriko , Aleff, Ross, Butz, Malinda, Hayashi, Ryosuke, Sato, Takahiko

Mayo Clinic

Investigative Opthalmology & Visual Science | February 27, 2019 | Volume: 60 | Issue: 2 | Pages: 779

10.1167/iovs.18-25760 | PMID 30811544 Get It